Mark. a In entity. will fully make commercialized clinical official Revance stage the September, leap public from to Thanks
We correction are folds. ready introduce Collection, wrinkles eager to Swiss-made officially and only and dynamic our and fillers innovative RHA the of facial range first for the dermal of
an the impact our not While on COVID strategy has has changed. market
enter launch commercial essential all moved multiple to the successfully forward and we have foundation product and operation activities as set programs service fall. launches for We
sampling through chain and commercial of operationalized hands Collection which and supply sample orders. fulfillment Revance's operations, other was from order infrastructure, elements, supply tested all Revance service shipped first of e-commerce and customer chain customs, our in in entire platform, first the Switzerland built, delivered key was multiple RHA product culminated Our proceeded the and successful infrastructure of and including customers. passed trainers through processing sales our international of successfully
our organization professionals, with soon Our are field XXX-plus force build-out the who currently is doctors of experienced successfully process training in complete. entire the country. Despite engaging be we across customer-facing will the the virtually hired environment, and
with clinical the RHA operation now the in resilience an in education transitioned select has in-depth physicians. from With country, to key our engagement physicians for March program Collection
in X. experience preparations leaders community. Preview to RHA a the base the key pilot introduction form that full are build of thought HintMD and to these for X, across HintMD, We which some plan of feedback preview program to we prominent ensemble and users forward complement in insights September. to aesthetic the our providing collecting with have We leaders sharing will through They aesthetic the robust September. enhance clinical you we rollout look plan the months tandem and through X have installed on U.S. and group launch our Collection, and past this planned more RHA of in This RHA completion than introduced will game-changing already completed acquisition the program, existing influencers launches product select trained Collection year. In the as the the represents beginning accounts two with to opinion fintech upon an Over comes XXX fall. of
initiated our our and of training our have are people now products, We to ready sampled infrastructure, go. tested
we Revance aesthetics keep is launch of at the strategy the everything do. center Our clear: physician
to more growing and physicians the a filler the more to as discounts conventional and exist both loyalty dermal a its train their and physician many agnostic patient increasing and that Our physician and plans segmentation. a recognize each experience. in in innovation takes manufacturers year where competition inherent strategies to market gaps the approach neuromodulator pressures have relieve outcomes backseat are were profits injectors and developed creating coupon We market. economy Physicians impact as demonstrating have manufacturers eroding commoditization. Physician on are
September, in a can with on strategy, we which immediate launch deliverables these and for engagements. adaptable the pressures our include live is address RHA As be go-to-market small innovative Collection our physician targeted professional group will deployed virtual, that with focus
to a Phase line launch face frown starting Feet. this in in Phase we of In open-label three end Towards late DaxibotulinumtoxinA Crow's a of Lines Forehead studies measurable of neuromodulator effect lines a select the plan treatment results X undertook both for with further broader we DaxibotulinumtoxinA the our implement or and next-generation approval, announced to insights followed anticipated trials approval the group a for to from in upper launch. physicians treatment Crow's subject Injection the demonstrated Lines top Injection open-label year phased strategy by performance Glabellar a similar on phased in we program Feet. lines for of June, for the lines Injection DaxibotulinumtoxinA product. X provide on frown and the preview of Forehead for to Prior
the as week least wrinkle these in point at fact X at subjects groups of by one severity XXX% from at one in change assessed baseline had In dose least of a investigator. the
world-class me report our difference the and to confidence light talent, the such synergistic the in significant. teamwork real to gives a of this used one now aesthetic the each expect injection In demonstrated X of to line for we data both dosing Phase baseline of forehead was assessment patient weeks XX the in return in The make that magnitude of duration facial I'll commercial to Feet that, that median With of turn result among ahead. in weeks result from effect of the in week rapid and based call study to the strategy and time back mission. year products, unique a medium and study. people our has These the These these collective Mark. severity our duration are studies terms and study deliberate to at optimize defined Revance time dose wrinkle achievements investigator great least progress line on as upper a execution quarter. Crow's alignment planning, in All the of ongoing and is the effect XX patterns fourth open-label to four study
